Cadrenal Therapeutics, INC 10-Q quarterly reports

Cadrenal Therapeutics reports a 35% reduction in net loss for Q1 2026, driven by decreased operating expenses, but faces substantial doubt regarding its ability to continue as a going concern.

Cadrenal Therapeutics reported a significant increase in net loss and cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern without further financing.

Cadrenal Therapeutics reported a significant increase in net loss and cash burn for the first half of 2025, while advancing its lead drug candidate tecarfarin towards a Phase 3 clinical trial.

Cadrenal Therapeutics' Q1 2025 results show a widened net loss due to increased research and development and general and administrative expenses, despite ongoing efforts to advance its lead drug candidate, tecarfarin.

Cadrenal Therapeutics reported a net loss of $2.4 million for the third quarter of 2024, with increased operating expenses and ongoing development of their lead drug candidate, tecarfarin.

Cadrenal Therapeutics reported a net loss of $4.06 million for the first half of 2024 and highlighted the need for additional funding to continue operations.

Cadrenal Therapeutics reported a net loss of $1.66 million for the first quarter of 2024, a significant decrease compared to the $5.17 million loss in the same period of 2023.